Updated Sep 28, 11:02 PM · 60 sources analyzed
Key Takeaways
Merck-Daiichi's I-DXd SCLC accelerated approval withdrawal signals the FDA wants randomized or more mature data in small cell lung cancer ADC programs.
Merck's $400M KRAS G12D licensing deal from SciBrunch intensifies pressure on Revolution Medicines and other pure-play RAS inhibitor developers.
Multiple Phase 2 and Phase 3 trials terminated this week across oncology and fibrosis, reflecting continued high attrition in early-to-mid-stage development.
🏆 Winner
Merck — secured global KRAS G12D rights for $400M while clarifying its ADC regulatory strategy, advancing on two oncology fronts simultaneously.
📉 Loser
Merck / Daiichi Sankyo (I-DXd program) — FDA rejection of the accelerated approval pathway for SCLC erases first-mover advantage and forces a costly strategy reset in a competitive disease area.
🔭 Watch Next
Revolution Medicines' upcoming Phase 2 KRAS G12D data — expected at ASCO or AACR in 2027 — will set the clinical benchmark that Merck's newly acquired SciBrunch asset must eventually clear.
Merck-Daiichi pull ifinatamab-deruxtecan accelerated approval bid for SCLC
Merck and Daiichi Sankyo withdrew their application seeking accelerated FDA approval of ifinatamab deruxtecan (I-DXd) for small cell lung cancer after the FDA signaled the existing data would not support a speedy clearance. Small cell lung cancer has almost no approved targeted options, making any ADC (antibody-drug conjugate) approval here a major commercial prize. The withdrawal erases a potential first-mover advantage for Merck-Daiichi in a disease where competitors are advancing their own assets, resetting the competitive timeline.
BioPharma Dive ↗Merck / Daiichi Sankyo
Ifinatamab deruxtecan (I-DXd) in Small cell lung cancer (SCLC)
The FDA indicated the data generated so far would not support accelerated approval. Detailed efficacy figures from the submission package have not been publicly released.
Why it matters
An FDA signal that existing data fall short of the accelerated approval bar is a meaningful evidentiary setback — it means Merck and Daiichi will need a more mature, likely confirmatory-strength dataset before re-engaging regulators, which could take years and cost the partnership its first-mover edge in SCLC.
What to watch
Watch for whether Merck and Daiichi announce a revised development plan for I-DXd in SCLC — including whether they pursue a full approval pathway — and how competing ADC programs from other sponsors respond to the regulatory bar now visible.
Merck / SciBrunch Therapeutics
Merck acquires global rights to SciBrunch Therapeutics' KRAS G12D inhibitor for $400M, expanding its RAS-targeted oncology portfolio.
The deal gives Merck a foothold in the KRAS G12D inhibitor race alongside Revolution Medicines and Bridgebio, intensifying competition in one of oncology's most commercially anticipated drug classes.
Why it matters
A $400M entry fee for what is likely an early-stage asset reflects the premium the market is placing on KRAS G12D access rights — Merck is essentially buying optionality in a class that could rival KRAS G12C (the first approved RAS inhibitor class) in commercial scale given G12D's higher prevalence in pancreatic cancer. For Revolution Medicines and other pure-play competitors, Merck's resources and oncology infrastructure raise the competitive stakes materially.
What to watch
Watch for Revolution Medicines to accelerate Phase 2 KRAS G12D disclosures at ASCO or AACR in 2027 to defend its clinical head start against Merck's newly acquired asset.
Merck / Daiichi Sankyo
Merck and Daiichi Sankyo withdraw accelerated approval application for ifinatamab deruxtecan (I-DXd) in small cell lung cancer after FDA signals insufficient data.
The FDA's informal rejection of the accelerated approval pathway for I-DXd in SCLC resets the competitive clock in a disease where no targeted therapies are approved and multiple ADC developers are racing to be first.
Why it matters
The FDA's bar for accelerated approval in SCLC is now visibly higher than the data Merck and Daiichi generated — this is an important signal for the entire ADC field in small cell lung cancer, suggesting that single-arm response data or short follow-up will not suffice and that randomized or more mature data will be needed, raising development costs and timelines for all competitors.
What to watch
Watch for Merck and Daiichi to announce a revised regulatory strategy for I-DXd in SCLC — including whether they pursue full approval with a randomized trial — and for competing programs to recalibrate their FDA engagement strategies accordingly.
Merck pays $400M for KRAS G12D inhibitor from China-based SciBrunch
Merck acquired global rights to SciBrunch Therapeutics' KRAS G12D inhibitor candidate for $400 million, entering a crowded but commercially high-value targeted oncology class.
Why it matters
Merck's willingness to pay $400M upfront for a preclinical or early-clinical KRAS G12D asset signals how seriously large pharma is treating RAS-targeted oncology as the next major drug class — and puts direct competitive pressure on Revolution Medicines and other pure-play RAS inhibitor developers who are further along clinically but now face a better-resourced rival.
What to watch
Watch for SciBrunch's asset to enter or advance in IND-enabling studies, and for Revolution Medicines' Phase 2 KRAS G12D data to set the clinical benchmark this program will need to clear.
This Phase 3 study evaluating progression-free survival (PFS) and overall survival (OS) by blinded independent central review is active but not yet recruiting additional patients. Full efficacy and safety data have not yet been released.
Why it matters
Platinum-resistant ovarian cancer remains one of oncology's hardest treatment challenges; a PFS or OS win here would open a meaningful commercial niche against a thin field of approved options.
Analysis
The study's active-not-recruiting status indicates enrollment is complete and the trial is maturing toward its primary readout — the next question is whether relacorilant's cortisol-receptor blocking mechanism translates into a survival benefit durable enough to satisfy regulators and convince oncologists to adopt it over standard chemotherapy backbones.
What to watch
Watch for a top-line PFS readout announcement from Corcept, likely in late 2026 or early 2027, which will determine whether a regulatory submission for this indication is viable.
The FDA indicated the data generated so far would not support accelerated approval. Detailed efficacy figures from the submission package have not been publicly released.
Why it matters
The withdrawal removes what would have been the first ADC approval in SCLC and hands competitors more runway to reach regulators first in a disease with roughly 35,000 new U.S. cases annually.
Analysis
An FDA signal that existing data fall short of the accelerated approval bar is a meaningful evidentiary setback — it means Merck and Daiichi will need a more mature, likely confirmatory-strength dataset before re-engaging regulators, which could take years and cost the partnership its first-mover edge in SCLC.
What to watch
Watch for whether Merck and Daiichi announce a revised development plan for I-DXd in SCLC — including whether they pursue a full approval pathway — and how competing ADC programs from other sponsors respond to the regulatory bar now visible.
The Phase 1/2 study of GDX012, a novel cell therapy for AML, has been terminated. No efficacy or safety outcome data have been disclosed in connection with the termination.
Why it matters
AML cell therapy remains a high-attrition space; another early termination reinforces how difficult it is to translate cell therapy success from lymphoma into myeloid malignancies.
Analysis
The termination without disclosed efficacy data leaves open whether GDX012 failed on safety, feasibility, or strategic reprioritization — any of which would be relevant for investors tracking Takeda's oncology pipeline depth and its appetite for continued cell therapy investment.
What to watch
Watch for any Takeda pipeline update or investor day commentary that clarifies whether GDX012 termination reflects a broader pullback from AML cell therapy or a one-asset decision.
The Phase 2 study evaluating BI 1839100 for cough in IPF and PPF patients has been terminated. No efficacy or safety data have been released in connection with the termination.
Why it matters
Cough in IPF is a debilitating, undertreated symptom with no approved therapy; another termination narrows an already thin development pipeline targeting this endpoint.
Analysis
Boehringer Ingelheim is already the market leader in IPF with nintedanib, so this termination likely reflects a scientific or tolerability signal rather than a lack of commercial motivation — investors tracking IPF pipeline diversification should note the continuing difficulty of isolating cough as a druggable symptom endpoint.
What to watch
Watch for whether Boehringer Ingelheim discloses a reason for termination or redirects BI 1839100 to another respiratory indication at an upcoming pulmonology congress.
The ZEAL Phase 2a/b study assessing the zibotentan and dapagliflozin combination in liver cirrhosis has been terminated. No efficacy or safety data have been disclosed alongside the termination.
Why it matters
Decompensated cirrhosis is a high-unmet-need area with almost no approved disease-modifying therapies; the termination of a combination approach pairing an endothelin-A antagonist with an SGLT2 inhibitor (a drug class that reduces kidney and liver stress) is a setback for this mechanistic strategy.
Analysis
AstraZeneca had positioned the zibotentan-dapagliflozin combination as a novel cardiorenal-hepatic asset; a Phase 2 termination without disclosed data weakens the case for this pairing and raises questions about whether the endothelin-A mechanism adds meaningful benefit on top of SGLT2 inhibition alone in this population.
What to watch
Watch for any AstraZeneca pipeline disclosure at EASL or a future investor update that clarifies whether dapagliflozin alone continues development in cirrhosis or whether the entire program is abandoned.
Merck / Daiichi Sankyo
Merck and Daiichi Sankyo withdraw accelerated approval application for ifinatamab deruxtecan (I-DXd) in small cell lung cancer after FDA signals insufficient data.
Why it matters
The FDA's informal rejection of the accelerated approval pathway for I-DXd in SCLC resets the competitive clock in a disease where no targeted therapies are approved and multiple ADC developers are racing to be first.
Analysis
The FDA's bar for accelerated approval in SCLC is now visibly higher than the data Merck and Daiichi generated — this is an important signal for the entire ADC field in small cell lung cancer, suggesting that single-arm response data or short follow-up will not suffice and that randomized or more mature data will be needed, raising development costs and timelines for all competitors.
What to watch
Watch for Merck and Daiichi to announce a revised regulatory strategy for I-DXd in SCLC — including whether they pursue full approval with a randomized trial — and for competing programs to recalibrate their FDA engagement strategies accordingly.
Merck / SciBrunch Therapeutics
Merck acquires global rights to SciBrunch Therapeutics' KRAS G12D inhibitor for $400M, expanding its RAS-targeted oncology portfolio.
Why it matters
The deal gives Merck a foothold in the KRAS G12D inhibitor race alongside Revolution Medicines and Bridgebio, intensifying competition in one of oncology's most commercially anticipated drug classes.
Analysis
A $400M entry fee for what is likely an early-stage asset reflects the premium the market is placing on KRAS G12D access rights — Merck is essentially buying optionality in a class that could rival KRAS G12C (the first approved RAS inhibitor class) in commercial scale given G12D's higher prevalence in pancreatic cancer. For Revolution Medicines and other pure-play competitors, Merck's resources and oncology infrastructure raise the competitive stakes materially.
What to watch
Watch for Revolution Medicines to accelerate Phase 2 KRAS G12D disclosures at ASCO or AACR in 2027 to defend its clinical head start against Merck's newly acquired asset.
Merck pays $400M for KRAS G12D inhibitor from China-based SciBrunch
Merck acquired global rights to SciBrunch Therapeutics' KRAS G12D inhibitor candidate for $400 million, entering a crowded but commercially high-value targeted oncology class.
Why it matters
KRAS G12D is one of the most prevalent oncogenic mutations in pancreatic, colorectal, and lung cancers; a validated small-molecule inhibitor targeting this variant could address a massive unmet need, though clinical proof of concept for G12D-specific agents remains early-stage across the field.
Analysis
Merck's willingness to pay $400M upfront for a preclinical or early-clinical KRAS G12D asset signals how seriously large pharma is treating RAS-targeted oncology as the next major drug class — and puts direct competitive pressure on Revolution Medicines and other pure-play RAS inhibitor developers who are further along clinically but now face a better-resourced rival.
What to watch
Watch for SciBrunch's asset to enter or advance in IND-enabling studies, and for Revolution Medicines' Phase 2 KRAS G12D data to set the clinical benchmark this program will need to clear.
Sotatercept Phase 2 completes in combined post-capillary pulmonary hypertension due to HFpEF
Merck's sotatercept Phase 2 study (MK-7962-007/A011-16) evaluating the drug in combined pre- and post-capillary pulmonary hypertension (Cpc-PH) due to heart failure with preserved ejection fraction has completed; no efficacy data have been released.
Why it matters
Cpc-PH due to HFpEF is a mechanistically distinct and treatment-refractory subset of pulmonary hypertension with no approved therapies; if sotatercept — already approved for pulmonary arterial hypertension — shows hemodynamic benefit here, it would substantially expand the addressable patient population.
Analysis
Sotatercept's approval in PAH (pulmonary arterial hypertension) established the activin signaling pathway as a druggable target in pulmonary vascular disease; the completion of this Phase 2 in Cpc-PH is an inflection point that will determine whether Merck pursues a label expansion into a far larger and historically drug-resistant population.
What to watch
Watch for Merck to present sotatercept Cpc-PH data at the American Heart Association or European Respiratory Society meetings in late 2026 or early 2027, which will define the expansion opportunity.
Xenon Pharmaceuticals completes Phase 2 of XEN1101 in major depressive disorder
Xenon Pharmaceuticals' Phase 2 double-blind, placebo-controlled study of XEN1101 — a Kv7 potassium channel opener (a drug that modulates neuronal excitability) — in major depressive disorder has completed; efficacy data have not yet been publicly released.
Why it matters
Kv7 channel modulation is a mechanistically differentiated approach to depression compared to existing monoamine-based therapies; a positive signal in MDD would validate a new ion channel target class for neuropsychiatric drug development.
Analysis
XEN1101 already has Phase 3 data in epilepsy, so Xenon's MDD program represents a bet on indication expansion into a far larger market — the upcoming data release will reveal whether the neural excitability mechanism translates from seizure control to mood disorders, a leap that has tripped up many CNS developers before.
What to watch
Watch for Xenon to release XEN1101 Phase 2 MDD results, likely at a major psychiatry or neuroscience conference in late 2026, which will determine whether a Phase 3 program in depression is warranted.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Merck's $400M acquisition of a KRAS G12D inhibitor from SciBrunch Therapeutics directly targets Revolution Medicines' lead competitive position in this mutation class. Revolution's clinical-stage KRAS G12D assets are currently the most advanced in the field, but Merck's entry as a well-resourced competitor increases pressure to accelerate data readouts and potential partnership or regulatory submissions.
MedCity News ↗